 |
인쇄하기
취소
|
Mypharm eyes 60% share in placenta market
For Mypharm, 2008 is a significant year for another reason.
Its Melsmon placenta injection has achieved a bigger market share, backed by better efficacy and safety, since March.
Industry sources generally agree that once Melsmon’s market share hovers the 40 percent level in a country, the player has the potential to reach 60 percent within this year.
Company officials ascribe the lates...
Its Melsmon placenta injection has achieved a bigger market share, backed by better efficacy and safety, since March.
Industry sources generally agree that once Melsmon’s market share hovers the 40 percent level in a country, the player has the potential to reach 60 percent within this year.
Company officials ascribe the lates...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.